Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma

scientific article published on 01 December 2004

Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2004.05.142
P698PubMed publication ID15570074

P2093author name stringPablo E Verde
Andreas Erbersdobler
Stefan B Hosch
Wolfram T Knoefel
Christoph A Klein
Jakob R Izbicki
Winfried Schraut
Nikolas H Stoecklein
Claus F Eisenberger
Andreas M Luebke
Matthias Peiper
Peter Scheunemann
Franziska Stern
P433issue23
P921main subjectpancreatic ductal adenocarcinomaQ18555956
invasive ductal carcinomaQ1671685
pancreatic ductal carcinomaQ8263002
P304page(s)4737-4745
P577publication date2004-12-01
P1433published inJournal of Clinical OncologyQ400292
P1476titleCopy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma
P478volume22

Reverse relations

cites work (P2860)
Q35886631Adjuvant and neoadjuvant treatment in pancreatic cancer
Q83973971Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin
Q91622958Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma
Q33489063Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis
Q35987242Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma
Q36463216Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification
Q21129230Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma
Q28078111HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists
Q43455376HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma
Q26824528Molecular landscape of pancreatic cancer: implications for current clinical trials
Q37125627Pancreatic carcinogenesis
Q36600002Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis
Q90164554The Implication of Cytogenetic Alterations in Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm Identified by Fluorescence In Situ Hybridization and Their Potential Diagnostic Utility
Q90682184The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA
Q37969932The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma
Q34494019The molecular targets for the diagnosis and treatment of pancreatic cancer
Q35793641The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Q54737674The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma.
Q48141659The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies
Q35811043Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

Search more.